These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32779783)

  • 1. Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19.
    Chistolini A; Ruberto F; Alessandri F; Santoro C; Barone F; Cristina Puzzolo M; Ceccarelli G; De Luca ML; Mancone M; Alvaro D; Pulcinelli FM; Martelli M; Foà R; Pugliese F;
    Br J Haematol; 2020 Aug; 190(4):e214-e218. PubMed ID: 32779783
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays.
    White D; MacDonald S; Edwards T; Bridgeman C; Hayman M; Sharp M; Cox-Morton S; Duff E; Mahajan S; Moore C; Kirk M; Williams R; Besser M; Thomas W
    Int J Lab Hematol; 2021 Feb; 43(1):123-130. PubMed ID: 32892505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study.
    Pereyra D; Heber S; Schrottmaier WC; Santol J; Pirabe A; Schmuckenschlager A; Kammerer K; Ammon D; Sorz T; Fritsch F; Hayden H; Pawelka E; Krüger P; Rumpf B; Traugott MT; Glaser P; Firbas C; Schörgenhofer C; Seitz T; Karolyi M; Pabinger I; Brostjan C; Starlinger P; Weiss G; Bellmann-Weiler R; Salzer HJF; Jilma B; Zoufaly A; Assinger A
    Cardiovasc Res; 2021 Dec; 117(14):2807-2820. PubMed ID: 34609480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus-induced coagulopathy during the course of disease.
    Friedrich MS; Studt JD; Braun J; Spahn DR; Kaserer A
    PLoS One; 2020; 15(12):e0243409. PubMed ID: 33332362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuation of therapeutic dose heparin for critically ill patients with COVID-19.
    Bradbury CA; Lawler PR; McVerry BJ; Zarychanski R;
    Intensive Care Med; 2023 Jul; 49(7):873-875. PubMed ID: 37256341
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.
    Trunfio M; Salvador E; Cabodi D; Marinaro L; Alcantarini C; Gaviraghi A; Trentalange A; Lipani F; Sciascia S; Roccatello D; Bonora S; Di Perri G; Calcagno A;
    Thromb Res; 2020 Dec; 196():432-434. PubMed ID: 33049598
    [No Abstract]   [Full Text] [Related]  

  • 7. DVT incidence and risk factors in critically ill patients with COVID-19.
    Chen S; Zhang D; Zheng T; Yu Y; Jiang J
    J Thromb Thrombolysis; 2021 Jan; 51(1):33-39. PubMed ID: 32607652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
    Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC
    Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
    Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
    Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients.
    de la Morena-Barrio ME; Bravo-Pérez C; Miñano A; de la Morena-Barrio B; Fernandez-Perez MP; Bernal E; Gómez-Verdu JM; Herranz MT; Vicente V; Corral J; Lozano ML
    Sci Rep; 2021 Apr; 11(1):7792. PubMed ID: 33833254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catastrophic Intracranial Hemorrhage in Two Critically Ill Patients with COVID-19.
    Carroll E; Lewis A
    Neurocrit Care; 2021 Feb; 34(1):354-358. PubMed ID: 32458333
    [No Abstract]   [Full Text] [Related]  

  • 12. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin generation in patients with COVID-19 with and without thromboprophylaxis.
    Campello E; Bulato C; Spiezia L; Boscolo A; Poletto F; Cola M; Gavasso S; Simion C; Radu CM; Cattelan A; Tiberio I; Vettor R; Navalesi P; Simioni P
    Clin Chem Lab Med; 2021 Jun; 59(7):1323-1330. PubMed ID: 33544518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of heparin thromboprophylaxis on thrombin generation in multiple myeloma patients.
    Chalayer E; Tardy-Poncet B; Montmartin A; Boussoualim K; Genthon A; Tardy B
    Br J Haematol; 2019 Jul; 186(2):337-339. PubMed ID: 30793294
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19-related laboratory coagulation findings.
    Devreese KMJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):36-42. PubMed ID: 34288440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
    Oudemans-van Straaten HM; van Schilfgaarde M; Molenaar PJ; Wester JP; Leyte A
    Crit Care; 2009; 13(6):R193. PubMed ID: 19958532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.
    Vrij AA; Oberndorff-Klein-Woolthuis A; Dijkstra G; de Jong AE; Wagenvoord R; Hemker HC; Stockbrügger RW
    J Thromb Thrombolysis; 2007 Oct; 24(2):175-82. PubMed ID: 17308963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity.
    Trunfio M; Salvador E; Gaviraghi A; Audagnotto S; Marinaro L; Motta I; Casciaro R; Ghisetti V; Fava C; Bonora S; Di Perri G; Calcagno A;
    Antivir Ther; 2020; 25(6):327-333. PubMed ID: 33506810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
    Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
    JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure.
    Fisher C; Patel VC; Stoy SH; Singanayagam A; Adelmeijer J; Wendon J; Shawcross DL; Lisman T; Bernal W
    J Crit Care; 2018 Feb; 43():54-60. PubMed ID: 28843665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.